GYRE
GYRE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$7.55
+5.15%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.14
From 52W high−14.88%
Volume1.18M
Market cap$800.55M
P/E (TTM)—
P/S (TTM)6.7x
Div yield—
Key dataSep 18, 2026
Open
$7.14
From 52W high
−14.88%
Volume
1.18M
Market cap
$800.55M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−56.1x
P/E (TTM)
—
RSI (14)
64.4
MomentumView details →
1D Return
+5.15%
YTD Return
+3.52%
SummaryUpdated Jun 1, 2026
Gyre Therapeutics, Inc. (NASDAQ:GYRE) is a pharmaceutical company founded in 2002 and headquartered in San Diego, California. The company went public in 2006 and operates as a subsidiary of GNI USA, Inc. Gyre specializes in developing and commercializing small-molecule drugs that target organ fibrosis, a medical condition where healthy tissue is replaced by scar tissue, leading to organ dysfunction. The company has successfully brought its lead drug to market and maintains an active pipeline of treatments for various fibrotic diseases affecting the lungs, liver, and other organs.
Similar companies
Latest newsMore news →